Cancer arises from somatic mutations accumulating within a cell, disrupting its normal growth and regulatory processes.  The genetic basis of cancer is increasingly understood through advancements in next-generation sequencing technologies, revealing the diverse mutational landscapes across cancer types and individual patients.  This has spurred significant progress in personalized medicine, moving beyond broad-spectrum therapies.  Identifying specific driver mutations through genomic profiling allows for the selection of targeted therapies, such as kinase inhibitors, aimed at disrupting the activity of oncogenic proteins.  Furthermore, understanding the tumor microenvironment and immune landscape through genomic analysis facilitates immunotherapy approaches, exploiting the patient's own immune system to target cancer cells.  However, challenges remain, including the presence of intratumoral heterogeneity, the development of resistance mechanisms, and the cost and accessibility of comprehensive genomic testing.  Ongoing research focuses on integrating multi-omics data, including transcriptomics, proteomics, and epigenomics, to refine predictive models and develop more effective personalized cancer treatments.